[go: up one dir, main page]

PE20241211A1 - METHODS FOR THE TREATMENT OF RELAPSED/RESISTANT FOLLICULAR LYMPHOMA WITH MOSUNETUZUMAB AND LENALIDOMIDE - Google Patents

METHODS FOR THE TREATMENT OF RELAPSED/RESISTANT FOLLICULAR LYMPHOMA WITH MOSUNETUZUMAB AND LENALIDOMIDE

Info

Publication number
PE20241211A1
PE20241211A1 PE2024000932A PE2024000932A PE20241211A1 PE 20241211 A1 PE20241211 A1 PE 20241211A1 PE 2024000932 A PE2024000932 A PE 2024000932A PE 2024000932 A PE2024000932 A PE 2024000932A PE 20241211 A1 PE20241211 A1 PE 20241211A1
Authority
PE
Peru
Prior art keywords
dose
mosunetuzumab
lenalidomide
administered
regimen
Prior art date
Application number
PE2024000932A
Other languages
Spanish (es)
Inventor
Catherine Granier
Andrea Knapp
Chi-Chung Li
Carol Elaine O'hear
Enkhtsetseg Purev
michael c Wei
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Publication of PE20241211A1 publication Critical patent/PE20241211A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Refiere a metodos que comprenden administrar una cantidad eficaz de mosunetuzumab y lenalidomida, en donde los sujetos: (a) tienen linfoma folicular (FL) recidivante y/o resistente (R/R) que expresa CD20, y (b) se trataron previamente con al menos un regimen de quimioinmunoterapia que comprende un anticuerpo monoclonal anti-CD20 (obinutuzumab o rituximab). En dicho metodo se administra mosunetuzumab por via intravenosa en un regimen de dosis, en donde: (a) el primer ciclo de dosis comprende una duracion de 21 dias, en donde se administra una primera dosis (C1D1) entre 0,02 mg a 4,0 mg, en el dia 1; una segunda dosis (C1D2) entre 0,05 mg a 20,0 mg, en el dia 8; y una tercera dosis (C1D3) entre 0,2 mg a 50,0 mg, en el dia 15; y (b) el segundo ciclo de dosis comprende una duracion de 28 dias y en donde se administra una dosis unica (C2D1) entre 0,2 mg a alrededor de 50 mg. Asimismo, se administra lenalidomida por via oral durante el segundo ciclo y posteriores en una dosis de 20 mg, y en los primeros 21 dias de cada ciclo de dosis. Ademas, en dicho regimen de dosis se administra un corticoesteroide. Tambien, refiere a que la combinacion de mosunetuzumab y lenalidomida genera una reduccion en la carga tumoral despues del regimen de dosis.It relates to methods comprising administering an effective amount of mosunetuzumab and lenalidomide, wherein the subjects: (a) have relapsed and/or refractory (R/R) follicular lymphoma (FL) expressing CD20, and (b) were previously treated with at least one chemoimmunotherapy regimen comprising an anti-CD20 monoclonal antibody (obinutuzumab or rituximab). In said method, mosunetuzumab is administered intravenously in a dose regimen, wherein: (a) the first dose cycle comprises a duration of 21 days, wherein a first dose (C1D1) between 0.02 mg to 4.0 mg is administered on day 1; a second dose (C1D2) between 0.05 mg to 20.0 mg, on day 8; and a third dose (C1D3) between 0.2 mg to 50.0 mg, on day 15; and (b) the second dose cycle comprises a duration of 28 days and where a single dose (C2D1) between 0.2 mg to approximately 50 mg is administered. Likewise, lenalidomide is administered orally during the second and subsequent cycles at a dose of 20 mg, and in the first 21 days of each dose cycle. In addition, a corticosteroid is administered in said dose regimen. Also, it refers to the fact that the combination of mosunetuzumab and lenalidomide generates a reduction in the tumor burden after the dose regimen.

PE2024000932A 2021-10-29 2021-10-29 METHODS FOR THE TREATMENT OF RELAPSED/RESISTANT FOLLICULAR LYMPHOMA WITH MOSUNETUZUMAB AND LENALIDOMIDE PE20241211A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/057439 WO2023075798A1 (en) 2021-10-29 2021-10-29 Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide

Publications (1)

Publication Number Publication Date
PE20241211A1 true PE20241211A1 (en) 2024-06-06

Family

ID=86158448

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024000932A PE20241211A1 (en) 2021-10-29 2021-10-29 METHODS FOR THE TREATMENT OF RELAPSED/RESISTANT FOLLICULAR LYMPHOMA WITH MOSUNETUZUMAB AND LENALIDOMIDE

Country Status (7)

Country Link
JP (1) JP2024540044A (en)
KR (1) KR20240093915A (en)
AU (1) AU2021471006A1 (en)
CA (1) CA3236111A1 (en)
MX (1) MX2024005105A (en)
PE (1) PE20241211A1 (en)
WO (1) WO2023075798A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3968993A1 (en) * 2019-05-14 2022-03-23 F. Hoffmann-La Roche AG Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma

Also Published As

Publication number Publication date
WO2023075798A1 (en) 2023-05-04
CA3236111A1 (en) 2023-05-04
AU2021471006A1 (en) 2024-05-16
MX2024005105A (en) 2024-05-14
WO2023075798A9 (en) 2023-06-29
JP2024540044A (en) 2024-10-31
KR20240093915A (en) 2024-06-24

Similar Documents

Publication Publication Date Title
CL2020002075A1 (en) Methods for treating cancer with anti-pd1 antibodies.
CN110354266A (en) Combination Therapies Used to Treat Cancer
JP2019519498A (en) Combination therapy of HDAC inhibitor and PD-1 inhibitor
AR113777A1 (en) METHODS OF ADMINISTRATION OF AN IMMUNOTHERAPY WITH RECEPTORS OF CHEMERIC ANTIGENS
MX2022005596A (en) DOSAGE REGIME FOR ANTI-DLL3 AGENTS.
MX2021001083A (en) DOSAGE REGIMEN FOR BISECIFIC ANTIBODIES AGAINST BCMA-CD3.
Perz et al. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia
AR105027A1 (en) METHODS OF TREATMENT OF LOCALLY ADVANCED OR METASTASIC BREAST CANCER USING ANTAGONISTS OF THE PD-1 AND TAXAN AXIS
PE20221338A1 (en) METHODS OF TREATMENT OF SMALL CELL LUNG CANCER WITH FORMULATIONS OF LURBINECTEDIN
MX2021013910A (en) METHODS FOR ADMINISTERING AN ANTI-CD38 ANTIBODY TO TREAT MULTIPLE MYELOMA.
RU2010151660A (en) METHODS FOR TREATING MULTIPLE MYELOMA
UY39673A (en) SOTORASIB DOSAGE REGULAR
MX2023000187A (en) DOSAGE OF VIBEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER.
MX2025005378A (en) Methods for the treatment of cardiovascular disease
RU2011117293A (en) COMPOSITION FOR TREATING A DISEASE
PE20241211A1 (en) METHODS FOR THE TREATMENT OF RELAPSED/RESISTANT FOLLICULAR LYMPHOMA WITH MOSUNETUZUMAB AND LENALIDOMIDE
MX2021014103A (en) Bryostatin compounds for enhancement of immunotherapy.
AR125296A1 (en) METHODS FOR THE TREATMENT OF CANCER WITH SUBCUTANEOUS ADMINISTRATION OF ANTI-PD1 ANTIBODIES
Atallah-Yunes et al. Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma
PE20250161A1 (en) Doses for treatment with bispecific antibodies anti-CD20/anti-CD3 in elderly patients
Jurczak et al. The use of Yttrium-90 Ibritumomab Tiuxetan (90 Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation
Khalil et al. Rare Isolated Renal Involvement with Marginal Zone B Cell Lymphoma: A Case Report with Literature Review of Contemporary Management Strategies
Sawalha et al. Rituximab dosing in B cell lymphoma
RU2008140661A (en) APPLICATION OF ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES IN A PATIENT WITH AN INadequate RESPONSE TO TNF-ALPH INHIBITOR
Begna et al. Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant